Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination With Carboplatin and Paclitaxel As Second-Line Treatment in Patients With Unresectable Stage III or Stage IV Melanoma
Axel Hauschild(Kiel University), Ulrich Keilholz(Berliner Hochschule für Technik), John M. Kirkwood(UPMC Hillman Cancer Center), Uwe Trefzer(Goethe University Frankfurt), Adil Daud(Memorial Sloan Kettering Cancer Center), J. Michael White(Goethe University Frankfurt), Dirk Schadendorf(University of Mannheim), Stephan Grabbe(Goethe University Frankfurt), Alexander M.M. Eggermont(Institut Gustave Roussy), Peter Hersey(Royal Prince Alfred Hospital), Steven O’Day, Sanjiv S. Agarwala(Goethe University Frankfurt), David Hogg(Goethe University Frankfurt), Christian Peschel(Technical University of Munich), Caroline Robert(Centre National de la Recherche Scientifique), Chenghua Xia(Goethe University Frankfurt), Kiran Patel(Goethe University Frankfurt), Claus Garbe(University Children's Hospital Tübingen), Jens Gille(Emory University), René González(University of Colorado Denver)
Cited by 545
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.8k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
|Journal of Clinical Oncology|2015|2.1k
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
|New England Journal of Medicine|2018|1.8k